FDA proposes new rules for heart defibrillators

(AP)—The Food and Drug Administration will require makers of heart-zapping defibrillators to submit more data on their safety and effectiveness following years of recalls of the emergency devices.

Defibrillators use electric shocks to jolt the heart back to normal after patients collapse from . Once used exclusively in emergency rooms, they are now found in schools, office buildings and other public places.

The devices have been plagued by design and manufacturing flaws for years. The says it has received 45,000 reports of problems with defibrillators between 2005 and 2012.

Currently the FDA approves defibrillators through a fast-track process reserved for devices similar to ones already on the market.

The FDA proposal, when finalized, will require manufacturers to submit more extensive testing documentation before new defibrillators can be marketed.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA wants stricter testing for defibrillators

Jan 21, 2011

(AP) -- The Food and Drug Administration is recommending stricter safety measures for heart-zapping defibrillators after years of increasing problems with the emergency medical devices.

Heart defibrillator company signs decree

May 01, 2008

The U.S. Food and Drug Administration said Medtronic Inc. has agreed to comply with FDA rules in manufacturing its external heart defibrillators.

Welch Allyn AED-10 defibrillators recalled

Nov 07, 2007

The U.S. Food and Drug Administration announced the recall of Welch Allyn AED-10 automatic external defibrillators due to possibly defective circuit boards.

Recommended for you

Time to take notice and tackle heart failure

14 hours ago

Experts have sounded a call to action for policy makers at local, national, and international levels to promote heart failure prevention, improve heart failure awareness among healthcare professionals, ensure ...

Hopes dashed for an agent to prevent reperfusion injury

17 hours ago

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective ...

User comments